A gel that delivers a new treatment for diabetic foot ulcers
Official title: Cutaneous Gel Delivering an Intriguing MOA Therapeutic to Treat DFU
Funded at Lynntech, INC. · NIH-10921751 · Data updated 2026-11-12
This study is testing a special gel that helps deliver a medicine to speed up the healing of diabetic foot ulcers, which are painful sores that can happen to people with diabetes.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lynntech, INC. NIH-funded |
| Lab location | 1 site (College Station, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $343,708 |
| NIH project number | 1R43DK135281-01A1 |
| Project ID | NIH-10921751 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with diabetic foot ulcers who are struggling with current treatment options.
✕Less likely to help
Patients without diabetes or those who do not have diabetic foot ulcers may not benefit from this research.
What this research studies
This research focuses on developing a specialized gel that can deliver a small molecule therapeutic aimed at improving the healing of diabetic foot ulcers (DFUs). DFUs are a serious complication of diabetes that can lead to severe health issues, including amputations. The gel is designed for controlled delivery of the therapeutic, which has a unique mechanism of action to enhance healing. By addressing the challenges of current DFU treatments, this project aims to provide a more effective solution for patients suffering from this debilitating condition.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment for diabetic foot ulcers, potentially reducing the need for amputations and improving patient quality of life.
How similar studies have gone: Previous research has shown promise in using controlled delivery systems for therapeutic agents, indicating potential success for this novel approach.
Where this research is happening
-
Lynntech, INC.
College Station, United States Active
Researchers
- Principal investigator: Sharma, Anjal C — Lynntech, INC.
- Study coordinator: Sharma, Anjal C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.